In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 696 ( 2023-05-17)
Abstract:
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that can cause acute and chronic arthritogenic disease. Several candidate CHIKV vaccines have advanced to clinical trials, and Raju et al . describe human B cell responses to a CHIKV-like particleâadjuvanted vaccine candidate (PXVX0317). Immunization induced neutralizing antibody responses against multiple CHIKV genotypes in all vaccinees. CHIKV-specific B cells were detected in peripheral blood up to 6 months after immunization, and monoclonal Abs (mAbs) generated from these B cells included both broadly reactive clones and genotype-specific mAbs. MAbs with the greatest passive protective efficacy in a mouse model of CHIKV also protected against related arthritogenic alphaviruses. Two broadly neutralizing mAbs were shown to target the apex of the E2 glycoprotein B domain. These findings demonstrate how the PXVX0317 vaccine can induce broadly protective B cell responses. —CNF
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.ade8273
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink